TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announces that it has completed Phase I of its 2006 scientific plan advancing Nanobac’s claim that Calcifying Nano Particles (CNPs) are pathogens. Concurrent results from scientific research conducted at the Mayo Clinic, NASA Johnson Space Center, University of California at San Francisco, and Shantou University Medical Center demonstrate that CNPs can induce inflammation, calcification and thrombosis. Disease states such as atherosclerosis (cardiovascular disease) and stone forming diseases such as Kidney Stones, Gall Stones and Prostate Stones are all associated with CNPs. The results of studies concerning self replication and Koch’s postulates are currently being analyzed. The results of the studies will be detailed in subsequent releases.
